Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy
• Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP.
Gespeichert in:
| Autor*in: |
Leclair-Visonneau, Laurène [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
5 |
|---|
| Übergeordnetes Werk: |
Enthalten in: SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE - Kanuri, Swapna ELSEVIER, 2015, official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:146 ; year:2016 ; pages:35-39 ; extent:5 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.clineuro.2016.04.021 |
|---|
| Katalog-ID: |
ELV024436097 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV024436097 | ||
| 003 | DE-627 | ||
| 005 | 20230623173902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clineuro.2016.04.021 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016010000008.pica |
| 035 | |a (DE-627)ELV024436097 | ||
| 035 | |a (ELSEVIER)S0303-8467(16)30155-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 600 |a 690 |q VZ |
| 084 | |a 51.00 |2 bkl | ||
| 084 | |a 51.32 |2 bkl | ||
| 100 | 1 | |a Leclair-Visonneau, Laurène |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy |
| 264 | 1 | |c 2016 | |
| 300 | |a 5 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. | ||
| 650 | 7 | |a Neuroprotection |2 Elsevier | |
| 650 | 7 | |a Controlled-trial |2 Elsevier | |
| 650 | 7 | |a Progressive supranuclear palsy |2 Elsevier | |
| 650 | 7 | |a Sodium valproate |2 Elsevier | |
| 700 | 1 | |a Rouaud, Tiphaine |4 oth | |
| 700 | 1 | |a Debilly, Bérangère |4 oth | |
| 700 | 1 | |a Durif, Franck |4 oth | |
| 700 | 1 | |a Houeto, Jean-Luc |4 oth | |
| 700 | 1 | |a Kreisler, Alexandre |4 oth | |
| 700 | 1 | |a Defebvre, Luc |4 oth | |
| 700 | 1 | |a Lamy, Estelle |4 oth | |
| 700 | 1 | |a Volteau, Christelle |4 oth | |
| 700 | 1 | |a Nguyen, Jean-Michel |4 oth | |
| 700 | 1 | |a Dily, Séverine Le |4 oth | |
| 700 | 1 | |a Damier, Philippe |4 oth | |
| 700 | 1 | |a Boutoleau-Bretonnière, Claire |4 oth | |
| 700 | 1 | |a Lejeune, Pascal |4 oth | |
| 700 | 1 | |a Derkinderen, Pascal |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Kanuri, Swapna ELSEVIER |t SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |d 2015 |d official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology |g Amsterdam [u.a.] |w (DE-627)ELV013090054 |
| 773 | 1 | 8 | |g volume:146 |g year:2016 |g pages:35-39 |g extent:5 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.clineuro.2016.04.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a GBV_ILN_40 | ||
| 936 | b | k | |a 51.00 |j Werkstoffkunde: Allgemeines |q VZ |
| 936 | b | k | |a 51.32 |j Werkstoffmechanik |q VZ |
| 951 | |a AR | ||
| 952 | |d 146 |j 2016 |h 35-39 |g 5 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
l l v llv |
|---|---|
| matchkey_str |
leclairvisonneaulaurnerouaudtiphainedebi:2016----:admzdlcbcnrletilfoimapotipor |
| hierarchy_sort_str |
2016 |
| bklnumber |
51.00 51.32 |
| publishDate |
2016 |
| allfields |
10.1016/j.clineuro.2016.04.021 doi GBVA2016010000008.pica (DE-627)ELV024436097 (ELSEVIER)S0303-8467(16)30155-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Leclair-Visonneau, Laurène verfasserin aut Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate Elsevier Rouaud, Tiphaine oth Debilly, Bérangère oth Durif, Franck oth Houeto, Jean-Luc oth Kreisler, Alexandre oth Defebvre, Luc oth Lamy, Estelle oth Volteau, Christelle oth Nguyen, Jean-Michel oth Dily, Séverine Le oth Damier, Philippe oth Boutoleau-Bretonnière, Claire oth Lejeune, Pascal oth Derkinderen, Pascal oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:146 year:2016 pages:35-39 extent:5 https://doi.org/10.1016/j.clineuro.2016.04.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 146 2016 35-39 5 045F 610 |
| spelling |
10.1016/j.clineuro.2016.04.021 doi GBVA2016010000008.pica (DE-627)ELV024436097 (ELSEVIER)S0303-8467(16)30155-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Leclair-Visonneau, Laurène verfasserin aut Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate Elsevier Rouaud, Tiphaine oth Debilly, Bérangère oth Durif, Franck oth Houeto, Jean-Luc oth Kreisler, Alexandre oth Defebvre, Luc oth Lamy, Estelle oth Volteau, Christelle oth Nguyen, Jean-Michel oth Dily, Séverine Le oth Damier, Philippe oth Boutoleau-Bretonnière, Claire oth Lejeune, Pascal oth Derkinderen, Pascal oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:146 year:2016 pages:35-39 extent:5 https://doi.org/10.1016/j.clineuro.2016.04.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 146 2016 35-39 5 045F 610 |
| allfields_unstemmed |
10.1016/j.clineuro.2016.04.021 doi GBVA2016010000008.pica (DE-627)ELV024436097 (ELSEVIER)S0303-8467(16)30155-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Leclair-Visonneau, Laurène verfasserin aut Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate Elsevier Rouaud, Tiphaine oth Debilly, Bérangère oth Durif, Franck oth Houeto, Jean-Luc oth Kreisler, Alexandre oth Defebvre, Luc oth Lamy, Estelle oth Volteau, Christelle oth Nguyen, Jean-Michel oth Dily, Séverine Le oth Damier, Philippe oth Boutoleau-Bretonnière, Claire oth Lejeune, Pascal oth Derkinderen, Pascal oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:146 year:2016 pages:35-39 extent:5 https://doi.org/10.1016/j.clineuro.2016.04.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 146 2016 35-39 5 045F 610 |
| allfieldsGer |
10.1016/j.clineuro.2016.04.021 doi GBVA2016010000008.pica (DE-627)ELV024436097 (ELSEVIER)S0303-8467(16)30155-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Leclair-Visonneau, Laurène verfasserin aut Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate Elsevier Rouaud, Tiphaine oth Debilly, Bérangère oth Durif, Franck oth Houeto, Jean-Luc oth Kreisler, Alexandre oth Defebvre, Luc oth Lamy, Estelle oth Volteau, Christelle oth Nguyen, Jean-Michel oth Dily, Séverine Le oth Damier, Philippe oth Boutoleau-Bretonnière, Claire oth Lejeune, Pascal oth Derkinderen, Pascal oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:146 year:2016 pages:35-39 extent:5 https://doi.org/10.1016/j.clineuro.2016.04.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 146 2016 35-39 5 045F 610 |
| allfieldsSound |
10.1016/j.clineuro.2016.04.021 doi GBVA2016010000008.pica (DE-627)ELV024436097 (ELSEVIER)S0303-8467(16)30155-X DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Leclair-Visonneau, Laurène verfasserin aut Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy 2016 5 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate Elsevier Rouaud, Tiphaine oth Debilly, Bérangère oth Durif, Franck oth Houeto, Jean-Luc oth Kreisler, Alexandre oth Defebvre, Luc oth Lamy, Estelle oth Volteau, Christelle oth Nguyen, Jean-Michel oth Dily, Séverine Le oth Damier, Philippe oth Boutoleau-Bretonnière, Claire oth Lejeune, Pascal oth Derkinderen, Pascal oth Enthalten in Elsevier Science Kanuri, Swapna ELSEVIER SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE 2015 official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology Amsterdam [u.a.] (DE-627)ELV013090054 volume:146 year:2016 pages:35-39 extent:5 https://doi.org/10.1016/j.clineuro.2016.04.021 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 51.00 Werkstoffkunde: Allgemeines VZ 51.32 Werkstoffmechanik VZ AR 146 2016 35-39 5 045F 610 |
| language |
English |
| source |
Enthalten in SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE Amsterdam [u.a.] volume:146 year:2016 pages:35-39 extent:5 |
| sourceStr |
Enthalten in SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE Amsterdam [u.a.] volume:146 year:2016 pages:35-39 extent:5 |
| format_phy_str_mv |
Article |
| bklname |
Werkstoffkunde: Allgemeines Werkstoffmechanik |
| institution |
findex.gbv.de |
| topic_facet |
Neuroprotection Controlled-trial Progressive supranuclear palsy Sodium valproate |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| authorswithroles_txt_mv |
Leclair-Visonneau, Laurène @@aut@@ Rouaud, Tiphaine @@oth@@ Debilly, Bérangère @@oth@@ Durif, Franck @@oth@@ Houeto, Jean-Luc @@oth@@ Kreisler, Alexandre @@oth@@ Defebvre, Luc @@oth@@ Lamy, Estelle @@oth@@ Volteau, Christelle @@oth@@ Nguyen, Jean-Michel @@oth@@ Dily, Séverine Le @@oth@@ Damier, Philippe @@oth@@ Boutoleau-Bretonnière, Claire @@oth@@ Lejeune, Pascal @@oth@@ Derkinderen, Pascal @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013090054 |
| dewey-sort |
3610 |
| id |
ELV024436097 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV024436097</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623173902.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clineuro.2016.04.021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016010000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV024436097</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0303-8467(16)30155-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Leclair-Visonneau, Laurène</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuroprotection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Controlled-trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Progressive supranuclear palsy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sodium valproate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rouaud, Tiphaine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Debilly, Bérangère</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Durif, Franck</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Houeto, Jean-Luc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kreisler, Alexandre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Defebvre, Luc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lamy, Estelle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Volteau, Christelle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nguyen, Jean-Michel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dily, Séverine Le</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Damier, Philippe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boutoleau-Bretonnière, Claire</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lejeune, Pascal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Derkinderen, Pascal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Kanuri, Swapna ELSEVIER</subfield><subfield code="t">SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE</subfield><subfield code="d">2015</subfield><subfield code="d">official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013090054</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:146</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:35-39</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.clineuro.2016.04.021</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">146</subfield><subfield code="j">2016</subfield><subfield code="h">35-39</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Leclair-Visonneau, Laurène |
| spellingShingle |
Leclair-Visonneau, Laurène ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy |
| authorStr |
Leclair-Visonneau, Laurène |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013090054 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 600 - Technology 690 - Buildings |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate Elsevier |
| topic |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate |
| topic_unstemmed |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate |
| topic_browse |
ddc 610 ddc 600 bkl 51.00 bkl 51.32 Elsevier Neuroprotection Elsevier Controlled-trial Elsevier Progressive supranuclear palsy Elsevier Sodium valproate |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
t r tr b d bd f d fd j l h jlh a k ak l d ld e l el c v cv j m n jmn s l d sl sld p d pd c b b cbb p l pl p d pd |
| hierarchy_parent_title |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| hierarchy_parent_id |
ELV013090054 |
| dewey-tens |
610 - Medicine & health 600 - Technology 690 - Building & construction |
| hierarchy_top_title |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013090054 |
| title |
Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy |
| ctrlnum |
(DE-627)ELV024436097 (ELSEVIER)S0303-8467(16)30155-X |
| title_full |
Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy |
| author_sort |
Leclair-Visonneau, Laurène |
| journal |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| journalStr |
SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
35 |
| author_browse |
Leclair-Visonneau, Laurène |
| container_volume |
146 |
| physical |
5 |
| class |
610 610 DE-600 610 VZ 600 690 VZ 51.00 bkl 51.32 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Leclair-Visonneau, Laurène |
| doi_str_mv |
10.1016/j.clineuro.2016.04.021 |
| dewey-full |
610 600 690 |
| title_sort |
randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy |
| title_auth |
Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy |
| abstract |
• Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. |
| abstractGer |
• Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. |
| abstract_unstemmed |
• Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U GBV_ILN_40 |
| title_short |
Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy |
| url |
https://doi.org/10.1016/j.clineuro.2016.04.021 |
| remote_bool |
true |
| author2 |
Rouaud, Tiphaine Debilly, Bérangère Durif, Franck Houeto, Jean-Luc Kreisler, Alexandre Defebvre, Luc Lamy, Estelle Volteau, Christelle Nguyen, Jean-Michel Dily, Séverine Le Damier, Philippe Boutoleau-Bretonnière, Claire Lejeune, Pascal Derkinderen, Pascal |
| author2Str |
Rouaud, Tiphaine Debilly, Bérangère Durif, Franck Houeto, Jean-Luc Kreisler, Alexandre Defebvre, Luc Lamy, Estelle Volteau, Christelle Nguyen, Jean-Michel Dily, Séverine Le Damier, Philippe Boutoleau-Bretonnière, Claire Lejeune, Pascal Derkinderen, Pascal |
| ppnlink |
ELV013090054 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.clineuro.2016.04.021 |
| up_date |
2024-07-06T21:25:58.015Z |
| _version_ |
1803866507067785216 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV024436097</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623173902.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.clineuro.2016.04.021</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016010000008.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV024436097</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0303-8467(16)30155-X</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">600</subfield><subfield code="a">690</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">51.32</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Leclair-Visonneau, Laurène</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">5</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Inhibition of glycogen synthase kinase (GSK-3) is a therapeutic option for PSP. • We assessed the safety and efficacy of sodium valproate (VPA), a GSK-3 inhibitor, in PSP. • VPA was not effective as a disease-modifying agent in PSP.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Neuroprotection</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Controlled-trial</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Progressive supranuclear palsy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sodium valproate</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rouaud, Tiphaine</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Debilly, Bérangère</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Durif, Franck</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Houeto, Jean-Luc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kreisler, Alexandre</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Defebvre, Luc</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lamy, Estelle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Volteau, Christelle</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nguyen, Jean-Michel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dily, Séverine Le</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Damier, Philippe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Boutoleau-Bretonnière, Claire</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lejeune, Pascal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Derkinderen, Pascal</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Kanuri, Swapna ELSEVIER</subfield><subfield code="t">SUDDEN CARDIAC DEATH IN MALIGNANT BILEAFLET MITRAL VALVE PROLAPSE</subfield><subfield code="d">2015</subfield><subfield code="d">official publication of the Netherlands Society of Neurology and the Netherlands Society of Neurosurgery and the Flemish Society of Neurology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV013090054</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:146</subfield><subfield code="g">year:2016</subfield><subfield code="g">pages:35-39</subfield><subfield code="g">extent:5</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.clineuro.2016.04.021</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.00</subfield><subfield code="j">Werkstoffkunde: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">51.32</subfield><subfield code="j">Werkstoffmechanik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">146</subfield><subfield code="j">2016</subfield><subfield code="h">35-39</subfield><subfield code="g">5</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3992147 |